Targeted therapy with BRAF‐ and MEK‐Inhibitors (BRAFi and MEKi) provides an excellent therapeutic option for patients with malignant melanomas harbouring a BRAF‐Mutation.1 The gene discussed is MAP2K7; the disease is melanoma.